Cytokeratin 10 Antibody (KRT10/844 + KRT10/1275) - Azide and BSA Free, Novus Biologicals™

Cytokeratin 10

Monoclonal

1 mg/mL

Flow Cytometry 0.5 - 1 ug/million cells, Immunocytochemistry/Immunofluorescence 0.5 - 1 ug/ml, Immunohistochemistry-Paraffin 0.1 - 0.2 ug/ml, CyTOF-ready

BCIE, BIE, CK10, CK-10, cytokeratin 10, Cytokeratin-10, EHK, K10keratosis palmaris et plantaris, keratin 10, Keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et plantaris), keratin, type I cytoskeletal 10, keratin-10, KPP

Mouse

56.5 kDa

100 μg

Cytoskeleton Markers

3858

Human

Purified

Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), CyTOF

KRT10/844 + KRT10/1275

Unconjugated

PBS with No Preservative

KRT10

Recombinant human KRT10 protein

Protein A or G purified

RUO

Primary

This MAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Store at -20 to -80C. Avoid freeze-thaw cycles.

IgG1 κ